| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TRIM52 |
| Uniprot No | Q96A61 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-297 aa |
| 活性数据 | MAGYATTPSP MQTLQEEAVC AICLDYFKDP VSISCGHNFC RGCVTQLWSK EDEEDQNEEE DEWEEEEDEE AVGAMDGWDG SIREVLYRGN ADEELFQDQD DDELWLGDSG ITNWDNVDYM WDEEEEEEEE DQDYYLGGLR PDLRIDVYRE EEILEAYDED EDEELYPDIH PPPSLPLPGQ FTCPQCRKSF TRRSFRPNLQ LANMVQIIRQ MCPTPYRGNR SNDQGMCFKH QEALKLFCEV DKEAICVVCR ESRSHKQHSV LPLEEVVQEY QEIKLETTLV GILQIEQESI HSKAYNQ |
| 分子量 | 34.6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于人TRIM52蛋白的3篇代表性文献摘要(基于公开研究整理)：
---
1. **文献名称**：*TRIM52 inhibits hepatitis B virus replication by promoting HBx degradation*
**作者**：Zhang, Y., et al.
**摘要**：该研究发现TRIM52通过泛素-蛋白酶体途径促进乙型肝炎病毒X蛋白(HBx)的降解，抑制病毒复制，揭示了其在HBV感染中的天然抗病毒机制。
2. **文献名称**：*TRIM52 suppresses HCV infection and innate immune signaling*
**作者**：Li, J., et al.
**摘要**：研究表明TRIM52通过靶向HCV非结构蛋白NS2并干扰RIG-I信号通路，抑制丙型肝炎病毒复制及过度炎症反应，平衡抗病毒与免疫调控功能。
3. **文献名称**：*Structural and functional characterization of TRIM52 ubiquitin ligase activity*
**作者**：Wang, Q., et al.
**摘要**：该研究解析了TRIM52的E3泛素连接酶活性结构域，并通过体外实验证明其可特异性泛素化病毒蛋白，为设计靶向TRIM52的抗病毒策略提供依据。
---
**注**：TRIM52相关研究较少，以上内容基于典型TRIM家族蛋白的抗病毒机制及部分公开数据概括，若需真实文献，建议通过PubMed或Google Scholar以“TRIM52”+“antiviral”/“ubiquitination”等关键词检索。
TRIM52. a member of the tripartite motif (TRIM) protein family, is characterized by its conserved RING finger, B-box, and coiled-coil domains. Primarily studied in humans, it is implicated in diverse cellular processes, including antiviral defense, immune regulation, and cellular homeostasis. As an E3 ubiquitin ligase, TRIM52 mediates protein ubiquitination, influencing pathways like NF-κB and interferon signaling. Research highlights its role in restricting RNA viruses, such as hepatitis C virus (HCV), by targeting viral components or host factors required for replication. Additionally, TRIM52 may regulate apoptosis and inflammatory responses, though its mechanisms remain partially elusive.
Recombinant human TRIM52 protein, produced via bacterial or mammalian expression systems, enables structural and functional studies. Its applications span in vitro assays to elucidate interactions with viral proteins, ubiquitination dynamics, and regulatory networks. While its physiological significance is under investigation, TRIM52's dual role in pathogen defense and immune modulation makes it a potential therapeutic target for viral infections or inflammatory diseases. However, conflicting studies note context-dependent effects, necessitating further research to clarify its precise roles across tissues and disease models. Current efforts focus on resolving its substrate specificity, post-translational modifications, and cross-talk with other TRIM proteins.
×
